Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 4/20 | 0.53 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL949228 | 0.96 | NR5A1 (0.58) | LTA4HNR5A1TSHRRAB9AGAA | |
| SCHEMBL948700 | 0.94 | NR5A1 (0.61) | LTA4HNR5A1TSHRRAB9AGAA | |
| SCHEMBL10993242 | 0.94 | CYP2D6 (0.59) | LTA4HCYP3A4CYP2D6RAB9ACYP1A2 | |
| SCHEMBL4748828 | 0.94 | NR5A1 (0.61) | LTA4HNR5A1TSHRRAB9AGAA | |
| SCHEMBL3924421 | 0.94 | NR5A1 (0.61) | LTA4HNR5A1TSHRRAB9AGAA | |
| SCHEMBL2832393 | 0.94 | NR5A1 (0.61) | LTA4HNR5A1TSHRRAB9AGAA | |
| SCHEMBL9706419 | 0.94 | NR5A1 (0.61) | LTA4HNR5A1TSHRRAB9AGAA | |
| SCHEMBL946779 | 0.94 | NR5A1 (0.61) | LTA4HNR5A1TSHRRAB9AGAA | |
| SCHEMBL163688 | 0.91 | LTA4H (0.52) | LTA4HCYP2D6CA12CA1CA2 | |
| SCHEMBL10987443 | 0.91 | CYP2D6 (0.56) | LTA4HNR5A1CYP3A4CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3156388-B1 | LIQUID CRYSTAL COMPOUND HAVING CF2O BONDING GROUP AND TOLANE BACKBONE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC CORP (JP) | 2019-01-30 | — | — | EP | disclosed |
| US-20180333406-A1 | BENZONAPTHYRIDINE COMPOSITIONS AND USES THEREOF | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2018-11-22 | — | — | US | disclosed |
| US-9879183-B2 | Liquid crystal compound having CF2O bonding group and tolan skeleton, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2018-01-30 | — | — | US | disclosed |
| US-9879183-B2 | Liquid crystal compound having CF2O bonding group and tolan skeleton, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2018-01-30 | — | — | US | disclosed |
| EP-2440245-B1 | BENZONAPHTHYRIDINE-CONTAINING VACCINES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2017-12-06 | — | — | EP | disclosed |
| US-9649373-B2 | Neoseptins: small molecule adjuvants | THE SCRIPPS INSTITUTE (US) | 2017-05-16 | — | — | US | disclosed |
| US-20170107427-A1 | LIQUID CRYSTAL COMPOUND HAVING CF2O BONDING GROUP AND TOLAN SKELETON, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2017-04-20 | — | — | US | disclosed |
| US-20170107427-A1 | LIQUID CRYSTAL COMPOUND HAVING CF2O BONDING GROUP AND TOLAN SKELETON, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2017-04-20 | — | — | US | disclosed |
| EP-3156388-A1 | LIQUID CRYSTAL COMPOUND HAVING CF2O BONDING GROUP AND TOLANE BACKBONE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC Corporation (JP) | 2017-04-19 | — | — | EP | disclosed |
| EP-2512478-B1 | HOMOGENEOUS SUSPENSION OF IMMUNOPOTENTIATING COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2017-04-19 | — | — | EP | disclosed |
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
| WO-2004072025-A2 | SUBSTITUTED N-ARYLHETEROCYCLES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-26 | — | — | WO | disclosed |
| EP-0597701-B1 | Conjugated enyne derivative and liquid crystal composition | CHISSO CORP (JP) | 1997-04-16 | — | — | EP | disclosed |
| US-5370819-A | Low viscosity | CHISSO CORPORATION (JP) | 1994-12-06 | — | — | US | disclosed |
| EP-0597701-A1 | Conjugated enyne derivative and liquid crystal composition | CHISSO CORPORATION (JP) | 1994-05-18 | — | — | EP | disclosed |
| US-5242618-A | Liquid crystals | MERCK PATENT GESELLSCHAFT (DE) | 1993-09-07 | — | — | US | disclosed |
| EP-0374849-A2 | Liquid-crystal derivatives of nitrogen-containing heterocyclic compounds as components of a liquid-crystal material, and a liquid-crystal material | PAVLJUCHENKO, Assya Iosifovna (RU) | 1990-06-27 | — | — | EP | disclosed |
| US-4720567-A | Novel diacetylenic and polydiacetylenic compositions | HOECHST CELANESE CORPORATION (US) | 1988-01-19 | — | — | US | disclosed |
| US-4711532-A | Novel diacetylenic and polydiacetylenic compositions | HOECHST CELANESE CORPORATION (US) | 1987-12-08 | — | — | US | disclosed |
| US-4703096-A | Novel diacetylenic and polydiacetylenic compositions | CELANESE CORPORATION (US) | 1987-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | CYP11B2, CYP11B1, CYP1A1 | LTA4H 1141/4885NR5A1 460/4885CYP3A4 13/4885 |
| US-20170107427-A1 | LIQUID CRYSTAL COMPOUND HAVING CF2O BONDING GROUP AND TOLAN SKELETON, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | PIEZO1, TLN1, TCOF1 | LTA4H 1298/4885NR5A1 3423/4885CYP3A4 2658/4885 |
| US-20180333406-A1 | BENZONAPTHYRIDINE COMPOSITIONS AND USES THEREOF | HAMP, MAVS, MYD88 | LTA4H 2416/4885NR5A1 2565/4885CYP3A4 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.